Atai Beckley N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
Netherlands
Country
Netherlands
Business Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN, , 1183
Mailing Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN, , 1183
Phone
49 89 2153 9035
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
-$40.22M
Net Income
$45.03M
Cash & Equivalents
$-0.25
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 8-K Current report of material events | November 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
| 3 Initial insider ownership report | November 6, 2025 | View on SEC |
| 3 Initial insider ownership report | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
| 8-K Current report of material events | November 5, 2025 | View on SEC |
Material Events
8-K
Other
December 5, 2025
Low Impact
- Atai Beckley N.V. filed a prospectus supplement with the SEC to officially register common shares.
- These shares were previously issued as part of the acquisition of Beckley Psytech Limited.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.